Literature DB >> 9607815

Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy.

J A Lorenzo1, A Naprta, Y Rao, C Alander, M Glaccum, M Widmer, G Gronowicz, J Kalinowski, C C Pilbeam.   

Abstract

We measured the effects of ovariectomy on the bone mass of mice that lacked type I interleukin-1 receptor (IL-I R1 -/- mice) in two genetic backgrounds (C57BL/6 x 129/Sv and C57BL/6) to investigate the role of interleukin-1 in the actions of estrogen on bone. At three weeks after surgery, ovariectomized wild-type mice decreased trabecular bone volume in the proximal humerus by 70% in a C57BL/6 x 129/Sv background and 48% in a C57BL/6 background compared to sham-operated controls. In contrast, there was no significant decrease in trabecular bone mass in IL-1 R1 -/- mice after ovariectomy. The estrogen status of all groups was confirmed by measurement of uterine wet weight. These results demonstrate that a functional IL-1 response pathway is required for mice to lose trabecular bone mass after ovariectomy in this model and they imply that IL-1 is an important mediator of the effects of ovariectomy on bone mass. Hence, therapeutic interventions that block the effects of IL-1 on bone may be beneficial for treating diseases of rapid bone loss such as post-menopausal osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607815     DOI: 10.1210/endo.139.6.6128

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  35 in total

1.  M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss.

Authors:  S Cenci; M N Weitzmann; M A Gentile; M C Aisa; R Pacifici
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha.

Authors:  S Cenci; M N Weitzmann; C Roggia; N Namba; D Novack; J Woodring; R Pacifici
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 3.  Pathogenesis of postmenopausal osteoporosis.

Authors:  L G Raisz
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

4.  Interactions between immune and bone cells: new insights with many remaining questions.

Authors:  J Lorenzo
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

5.  Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator.

Authors:  Simone Cenci; Gianluca Toraldo; M Neale Weitzmann; Cristiana Roggia; Yuhao Gao; Wei Ping Qian; Oscar Sierra; Roberto Pacifici
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-15       Impact factor: 11.205

6.  Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand.

Authors:  Jau-Yi Li; Hesham Tawfeek; Brahmchetna Bedi; Xiaoying Yang; Jonathan Adams; Kristy Y Gao; Majd Zayzafoon; M Neale Weitzmann; Roberto Pacifici
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 7.  Paget disease of bone.

Authors:  G David Roodman; Jolene J Windle
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

Review 8.  Pathogenesis of osteoporosis: concepts, conflicts, and prospects.

Authors:  Lawrence G Raisz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

9.  Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling.

Authors:  Jong-Ho Lee; Ha-Neui Kim; Daum Yang; Kyoungsuk Jung; Hyun-Man Kim; Hong-Hee Kim; Hyunil Ha; Zang Hee Lee
Journal:  J Biol Chem       Date:  2009-03-19       Impact factor: 5.157

10.  Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases.

Authors:  A Nemetz; M Tóth; M A García-González; T Zágoni; J Fehér; A S Peña; Z Tulassay
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.